IBRX Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -19.69%. ImmunityBio, Inc.'s return on equity of -- beat Moderna, Inc.'s return on equity of -30.18%.

ImmunityBio, Inc. has a consensus price target of $11.80, signalling upside risk potential of 98.49%. On the other hand Moderna, Inc. has an analysts' consensus of $39.00 which suggests that it could fall by -7.65%. Given that ImmunityBio, Inc. has higher upside potential than Moderna, Inc., analysts believe ImmunityBio, Inc. is more attractive than Moderna, Inc..

ImmunityBio, Inc. has a beta of 0.020, which suggesting that the stock is 98.006% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Moderna, Inc. quarterly revenues of $1B. ImmunityBio, Inc.'s net income of -$67.3M is higher than Moderna, Inc.'s net income of -$200M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 61.62x versus 7.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -287.29%. ImmunityBio, Inc.'s return on equity of -- beat Novavax, Inc.'s return on equity of --.

ImmunityBio, Inc. has a consensus price target of $11.80, signalling upside risk potential of 98.49%. On the other hand Novavax, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 48.15%. Given that ImmunityBio, Inc. has higher upside potential than Novavax, Inc., analysts believe ImmunityBio, Inc. is more attractive than Novavax, Inc..

ImmunityBio, Inc. has a beta of 0.020, which suggesting that the stock is 98.006% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.583, suggesting its more volatile than the S&P 500 by 158.251%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. ImmunityBio, Inc.'s net income of -$67.3M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 61.62x versus 1.38x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -316.61%. ImmunityBio, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

ImmunityBio, Inc. has a consensus price target of $11.80, signalling upside risk potential of 98.49%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1898.55%. Given that Plus Therapeutics, Inc. has higher upside potential than ImmunityBio, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than ImmunityBio, Inc..

ImmunityBio, Inc. has a beta of 0.020, which suggesting that the stock is 98.006% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. ImmunityBio, Inc.'s net income of -$67.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 61.62x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rapt Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of --. ImmunityBio, Inc.'s return on equity of -- beat Rapt Therapeutics, Inc.'s return on equity of -67.79%.

ImmunityBio, Inc. has a consensus price target of $11.80, signalling upside risk potential of 98.49%. On the other hand Rapt Therapeutics, Inc. has an analysts' consensus of $58.00 which suggests that it could grow by 0.49%. Given that ImmunityBio, Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Rapt Therapeutics, Inc..

ImmunityBio, Inc. has a beta of 0.020, which suggesting that the stock is 98.006% less volatile than S&P 500. In comparison Rapt Therapeutics, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.241%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapt Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Rapt Therapeutics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Rapt Therapeutics, Inc. quarterly revenues of --. ImmunityBio, Inc.'s net income of -$67.3M is lower than Rapt Therapeutics, Inc.'s net income of -$17.6M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Rapt Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 61.62x versus 54.16x for Rapt Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.